It is widely recognized that opportunistic screenings based on AST/ALT liver tests which are currently utilized by primary care physicians are insensitive and poorly specific for NAFLD (Drapkina et al., 2015; Petrick et al., 2015; Kwo et al., 2017). Here, GPT is linked to metabolic dysfunction-associated steatotic liver disease.